Skip to content

Cannabis research published in 2023

Page 7 of 9: studies 121 to 140 of 166, newest first. Back to the cannabis overview

Studies

Cannabis use and first onset Schizophrenia-like psychosis after traumatic brain injury in a patient with intracranial bullet

Journal of Substance Use February 7, 2023 M. Ergelen, M. Yalçın, Fikret Ferzan Gıynaş et al.

ABSTRACT Traumatic brain injury (TBI) is an important cause of mortality and morbidity worldwide. Cannabis use disorder and psychosis are rare but serious comorbidities seen after TBI. Recent studies indicate that the use of cannabis for self-medication may increase after TBI. Schizophrenia-like psychosis (SLP) is also seen, generally showing a late and gradual onset after TBI. Especially in...

Cannabis in Adolescence: Lasting Cognitive Alterations and Underlying Mechanisms.

Cannabis and Cannabinoid Research February 2023 Andrew F Scheyer, Steven R Laviolette, Anne-Laure Pelissier et al.

Cannabis consumption during adolescence is an area of particular concern, owing to changes in the social and political perception of the drug, and presents a scientific, medical, and economic challenge. Major social and economic interests continue to push toward cannabis legalization as well as pharmaceutical development. As a result, shifting perceptions of both legal and illicit cannabis use...

Smoked cannabis reduces peak cocaine plasma levels and subjective effects in a controlled drug administration study of polysubstance use in men.

Drug and Alcohol Dependence February 1, 2023 Conor H. Murray, Margaret Haney, Richard W Foltin et al.

Despite the high prevalence of polysubstance use, outcomes and potential risks associated with common drug combinations are not well characterized. Many individuals who use cocaine also use cannabis, yet little is known about how interactions between the two drugs might contribute to continued co-use. The aim of this double-blind, placebo-controlled study was to determine the physiological and...

Effects of Δ9-THC and Type-1 Cannabinoid Receptor Agonists in the Elevated Plus Maze Test of Anxiety: A Systematic Review and Meta-Analysis.

Cannabis and Cannabinoid Research February 2023 Lia P Iglesias, Lucas Bedeschi, Daniele C Aguiar et al.

Δ9-THC (the main active compound from Cannabis sativa) and related cannabinoids have been used as drugs of abuse and as medications. They induce a complex set of emotional responses in humans and experimental animals, consisting of either anxiolysis or heightened anxiety. These discrepant effects pose a major challenge for data reproducibility and for developing new cannabinoid-based medicines....

Adolescent Δ-9-tetrahydrocannabinol exposure induces differential acute and long-term neuronal and molecular disturbances in dorsal vs. ventral hippocampal subregions.

Neuropsychopharmacology February 2023 Marta De Felice, Chaochao Chen, Mar Rodríguez-ruiz et al.

Chronic exposure to Δ-9-tetrahydrocannabinol (THC) during adolescence is associated with long-lasting cognitive impairments and enhanced susceptibility to anxiety and mood disorders. Previous evidence has revealed functional and anatomical dissociations between the posterior vs. anterior portions of the hippocampal formation, which are classified as the dorsal and ventral regions in rodents,...

Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial.

JAMA Network Open February 1, 2023 C Austin Zamarripa, Tory R Spindle, Renuka Surujunarain et al.

Controlled clinical laboratory studies have shown that cannabidiol (CBD) can sometimes attenuate or exacerbate the effects of Δ9-tetrahydrocannabinol (Δ9-THC). No studies have evaluated differences in pharmacokinetics (PK) of Δ9-THC and pharmacodynamics (PD) between orally administered cannabis extracts that vary with respect to Δ9-THC and CBD concentrations. To compare the PK and PD of orally...

Perceptions about THC and CBD effects among adults with and without prior cannabis experience.

Addictive Behaviors February 2023 Toni C Spinella, Jeremy Bartholomeusz, Sherry H Stewart et al.

Cannabis is associated with a range of therapeutic and non-therapeutic, positive and negative effects. While some benefits and harms may be specific to individual cannabinoid constituents (THC, CBD), individual expectancies may also play a role. Evaluate the extent to which individuals hold expectancies about the effects of CBD, THC, and THC & CBD combined, and whether this differs with prior...

Effects of inhaled cannabis high in Δ9-THC or CBD on the aging brain: A translational MRI and behavioral study

Frontiers in Aging Neuroscience February 1, 2023 Aymen H. Sadaka, Justin Canuel, Marcelo Febo et al. 29 citations

With the recent legalization of inhaled cannabis for medicinal and recreational use, the elderly represents one of the newest, rapidly growing cohorts of cannabis users. To understand the neurobiological effects of cannabis on the aging brain, 19-20 months old mice were divided into three groups exposed to vaporized cannabis containing ~10% Δ9-THC, ~10% CBD, or placebo for 30 min each day....

THC and CBD: Similarities and differences between siblings.

Neuron February 1, 2023 Nephi Stella

Δ9-tetrahydrocannabinol (THC) and its sibling, cannabidiol (CBD), are produced by the same Cannabis plant and have similar chemical structures but differ dramatically in their mechanisms of action and effects on brain functions. Both THC and CBD exhibit promising therapeutic properties; however, impairments and increased incidence of mental health diseases are associated with acute and chronic...

Consumer Experiences with Delta-8-THC: Medical Use, Pharmaceutical Substitution, and Comparisons with Delta-9-THC

Cannabis and Cannabinoid Research February 1, 2023 Daniel J. Kruger, Jessica S Kruger

Introduction: Cannabis products containing delta-8-THC became widely available in most of the United States in late 2020 and rapidly became a significant source of revenue for hemp processing companies, especially in states where use of delta-9-THC remains illegal or requires professional authorization for medical use. Scientific research on the use of delta-8-THC is scarce, previous clinical...

The trajectory of two negative symptom dimensions in first-episode psychosis and the role of cannabis use: A 10-year follow-up study.

Schizophrenia Research January 25, 2023 H. M. Ihler, S. H. Lyngstad, E. Gardsjord et al.

OBJECTIVE To investigate the trajectories of diminished expression and apathy over 10 years. Further, to explore the effects of baseline- and persistent cannabis use on the development of diminished expression and apathy during follow-up, while controlling other potential sources and predictors of secondary negative symptoms. METHODS 351 participants with a first episode of non-affective...

State Cannabis Legalization and Psychosis-Related Health Care Utilization

JAMA Network Open January 25, 2023 Holly Elser, Keith Humphreys, Mathew V. Kiang et al.

Importance Psychosis is a hypothesized consequence of cannabis use. Legalization of cannabis could therefore be associated with an increase in rates of health care utilization for psychosis. Objective To evaluate the association of state medical and recreational cannabis laws and commercialization with rates of psychosis-related health care utilization. Design, Setting, and Participants...

Sex differences in adolescent cannabis vapor self-administration mediate enduring effects on behavioral flexibility and prefrontal microglia activation in rats.

bioRxiv : the preprint server for biology January 22, 2023 Timothy G. Freels, Sara R Westbrook, Hayden R Wright et al. preprint

Cannabis is the most used illicit drug in the United States. With many states passing legislation to permit its recreational use, there is concern that cannabis use among adolescents could increase dramatically in the coming years. Historically, it has been difficult to model real-world cannabis use to investigate the causal relationship between cannabis use in adolescence and behavioral and...

Substance Use and Attendance Motives of Electronic Dance Music (EDM) Event Attendees: A Survey Study

International Journal of Environmental Research and Public Health January 19, 2023 Koen Ponnet, Bert Hauspie, Nicky Dirkx et al. 21 citations

EDM event attendees are a high-risk population for substance use and associated adverse effects. The aim of this study was to examine substance use at EDM events, focusing on associations between attendance motives and substance use. Sociodemographic characteristics, event specifics, past-year use, and attendance motives were assessed through an online survey. Participants were 1345 Belgian EDM...

DOI: 10.3390/ijerph20031821 (opens in new tab) Ecstasy Cannabis Electronic dance music Attendance +1

An Ecological Examination of Indica Versus Sativa and Primary Terpenes on the Subjective Effects of Smoked Cannabis: A Preliminary Investigation

Cannabis and Cannabinoid Research January 16, 2023 Sarah A. Okey, Jack T. Waddell, Rishika Shah et al.

Background: The legal cannabis landscape has greatly outpaced scientific knowledge. Many popular cannabis claims, such as cultivar (colloquially referred to as strain) classification and terpene content producing different subjective effects, are unsubstantiated. This study examined, for the first time, whether cultivar classification (sativa/indica) and terpene content (caryophyllene,...

Predictive impact of different acute cannabis intoxication effects with regard to abstinence motivation and cessation of use

Scientific Reports January 13, 2023 Thomas Schnell, Christina-Marie Grömm, Nils Klöckner 3 citations

Cannabis use is a common risk factor for psychoses. But although prevalence of consumption as well as potency of cannabis increased, the incidence of schizophrenia remained stable. The discontinuation hypothesis suggests that a potential increase of psychoses incidence may be relativized by more frequent cessation of consumption due to higher rates of adverse psychosis-like intoxication effects...

Cannabis use is associated with low plasma endocannabinoid Anandamide in individuals with psychosis

Journal of Psychopharmacology January 12, 2023 Anahita Bassir Nia, C. Gibson, Sharron A Spriggs et al.

Background: Cannabis use suppresses the endocannabinoid system in healthy individuals. However, the association between cannabis use with the endocannabinoid system is understudied in individuals with psychosis despite the high rate of cannabis use in these individuals. Methods: We enrolled 83 individuals who were admitted to an inpatient psychiatric unit with psychotic presentations, and...

Effect of Cannabis on Memory Consolidation, Learning and Retrieval and Its Current Legal Status in India: A Review.

Biomolecules January 12, 2023 Nandi Niloy, Tousif Ahmed Hediyal, Chandrasekaran Vichitra et al.

Cannabis is one of the oldest crops grown, traditionally held religious attachments in various cultures for its medicinal use much before its introduction to Western medicine. Multiple preclinical and clinical investigations have explored the beneficial effects of cannabis in various neurocognitive and neurodegenerative diseases affecting the cognitive domains. Tetrahydrocannabinol (THC), the...

Investigating the "two-hit hypothesis": Effects of prenatal maternal immune activation and adolescent cannabis use on neurodevelopment in mice.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 10, 2023 Elisa Guma, Lani Cupo, Weiya Ma et al.

Prenatal exposure to maternal immune activation (MIA) and chronic adolescent cannabis use are both risk factors for neuropsychiatric disorders. However, exposure to a single risk factor may not result in major mental illness, indicating that multiple exposures may be required for illness onset. Here, we examine whether combined exposure to prenatal MIA and adolescent...

DOI: 10.1016/j.pnpbp.2022.110642 (opens in new tab) Full text (opens in new tab) Adolescent cannabis use Brain development Environmental risk factors Maternal immune activation +1